Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Riviciclib |
Synonyms | |
Therapy Description |
Riviciclib (P276-00) is an inhibitor of CDK1, CDK4, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 17363486, PMID: 32175313). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Riviciclib | P276-00|P276 | CDK1 Inhibitor 13 CDK4 Inhibitor 17 CDK9 Inhibitor 21 | Riviciclib (P276-00) is an inhibitor of CDK1, CDK4, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 17363486, PMID: 32175313). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|